XBiotech announces Phase I/II study results in Lancet Oncology

The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s novel, non-cytotoxic, anti-tumor therapy. The so called true human antibody therapy was reported to have an excellent safety profile.

The report describes comprehensive measures of patient performance during therapy with Xilonix. It was reported that overall, patients constitutional symptoms improved, including reduction in pain and fatigue.

A highlight of the report was the finding that almost two-thirds of patients assessed with a new form of X-ray imaging demonstrated physical recovery of lean body mass (which is another way of referring to muscle mass) but moreover, that these same patients had dramatic improvement in overall survival.

The importance of the article was suggested by the co-publication of a commentary piece written by world-renown researcher Dr Charles Dinarello.

XBiotech chairman and CEO John Simard noted that the company is certainly happy to see these very important findings recognized in the world’s premier cancer journal.

"I hope the wider dissemination of this scientific and clinical milestone helps drive the development of Xilonix therapy as well as others that work to control cancer using less toxic approaches," Simard added.